Chun-wang Yuan
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.
Journal: Alimentary pharmacology & therapeutics
Published: December 10, 2025
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).
Journal: Hepatology (Baltimore, Md.)
Published: July 13, 2025
Predicting Treatment Response to Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients using a Deep Learning-based Approach.
Journal: Current medical imaging
Published: November 11, 2024
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).
Journal: Journal of cachexia, sarcopenia and muscle
Published: March 14, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Journal: EClinicalMedicine
Published: January 10, 2024
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Journal: Signal transduction and targeted therapy
Published: June 14, 2022
Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features.
Journal: BMC medical imaging
Published: March 23, 2022
Incomplete radiofrequency ablation promotes the development of CD133+ cancer stem cells in hepatocellular carcinoma cell line HepG2 via inducing SOX9 expression.
Journal: Hepatobiliary & pancreatic diseases international : HBPD INT
Published: January 09, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026